{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T22:03:21Z","timestamp":1768946601446,"version":"3.49.0"},"reference-count":38,"publisher":"e-Century Publishing Corporation","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/rgvc7978","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:01:38Z","timestamp":1761814898000},"page":"4360-4370","source":"Crossref","is-referenced-by-count":0,"title":["Distinct molecular signatures of upper tract urothelial carcinoma in Southwestern Taiwan: implications for targeted therapy and disease progression"],"prefix":"10.62347","volume":"15","author":[{"given":"Cheng-Huang","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","unstructured":"Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernandez MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP and Thalmann GN. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017; 35: 379-387.","journal-title":"World J Urol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS and Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48.","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12885-021-07799-4","article-title":"Comparative analysis of patients with upper urinary tract urothelial carcinoma in black-foot disease endemic and non-endemic area","volume":"21","author":"Chang","year":"2021","unstructured":"Chang CW, Ou CH, Yu CC, Lo CW, Tsai CY, Cheng PY, Chen YT, Huang HC, Wu CC, Li CC and Lee HY. Comparative analysis of patients with upper urinary tract urothelial carcinoma in black-foot disease endemic and non-endemic area. BMC Cancer 2021; 21: 80.","journal-title":"BMC Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"129094","DOI":"10.1016\/j.chemosphere.2020.129094","article-title":"Association between arsenic exposure, DNA damage, and urological cancers incidence: a long-term follow-up study of residents in an arseniasis endemic area of northeastern Taiwan","volume":"266","author":"Tsai","year":"2021","unstructured":"Tsai TL, Kuo CC, Hsu LI, Tsai SF, Chiou HY, Chen CJ, Hsu KH and Wang SL. Association between arsenic exposure, DNA damage, and urological cancers incidence: a long-term follow-up study of residents in an arseniasis endemic area of northeastern Taiwan. Chemosphere 2021; 266: 129094.","journal-title":"Chemosphere"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Su CC, Lu JL, Tsai KY and Lian Ie B. Reduction in arsenic intake from water has different impacts on lung cancer and bladder cancer in an arseniasis endemic area in Taiwan. Cancer Causes Control 2011; 22: 101-108.","DOI":"10.1007\/s10552-010-9679-2"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/iju.14731","article-title":"Incidence and survival variations of upper tract urothelial cancer in Taiwan (2001-2010)","volume":"29","author":"Lin","year":"2022","unstructured":"Lin MY, Niu SW, Li WM, Lee HL, Chen LT, Wu WJ and Hwang SJ. Incidence and survival variations of upper tract urothelial cancer in Taiwan (2001-2010). Int J Urol 2022; 29: 121-127.","journal-title":"Int J Urol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"8241","DOI":"10.1073\/pnas.1119920109","article-title":"Aristolochic acid-associated urothelial cancer in Taiwan","volume":"109","author":"Chen","year":"2012","unstructured":"Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS and Grollman AP. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A 2012; 109: 8241-8246.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Yang HY, Chen PC and Wang JD. Chinese herbs containing aristolochic acid associated with renal failure and urothelial carcinoma: a review from epidemiologic observations to causal inference. Biomed Res Int 2014; 2014: 569325.","DOI":"10.1155\/2014\/569325"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"8201","DOI":"10.1007\/s00432-023-04771-6","article-title":"Trends in the incidence of urothelial carcinoma in Taiwan after the ban on aristolochic acid-containing Chinese herbal preparations, 2001-2018: a national population-based cohort study","volume":"149","author":"Liao","year":"2023","unstructured":"Liao CI, Fang HC, Lee PT, Hsu CY, Chen CL, Huang CW, Chen XY, Ou SH, Tsai CT and Chou KJ. Trends in the incidence of urothelial carcinoma in Taiwan after the ban on aristolochic acid-containing Chinese herbal preparations, 2001-2018: a national population-based cohort study. J Cancer Res Clin Oncol 2023; 149: 8201-8211.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"2022","volume":"20","author":"Flaig","year":"2022","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ and Gurski LA. NCCN Guidelines(R) Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw 2022; 20: 866-878.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupret","year":"2023","unstructured":"Roupret M, Seisen T, Birtle AJ, Capoun O, Comperat EM, Dominguez-Escrig JL, Gurses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, Pradere B, van Rhijn BWG, Shariat SF, Rai BP, Soria F, Soukup V, Wood RG, Xylinas EN, Masson-Lecomte A and Gontero P. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol 2023; 84: 49-64.","journal-title":"Eur Urol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/SPC.0b013e328309c72c","article-title":"Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond","volume":"2","author":"Cheng","year":"2008","unstructured":"Cheng T. Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. Curr Opin Support Palliat Care 2008; 2: 153-160.","journal-title":"Curr Opin Support Palliat Care"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.7150\/jca.48105","article-title":"Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)","volume":"12","author":"Ma","year":"2021","unstructured":"Ma X, Zhang Y, Wang S and Yu J. Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC). J Cancer 2021; 12: 584-594.","journal-title":"J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","article-title":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","volume":"8","author":"Ricciuti","year":"2022","unstructured":"Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Janne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD and Awad MM. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol 2022; 8: 1160-1168.","journal-title":"JAMA Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cncr.29826","article-title":"Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations","volume":"122","author":"Ross","year":"2016","unstructured":"Ross JS, Wang K, Khaira D, Ali SM, Fisher HA, Mian B, Nazeer T, Elvin JA, Palma N, Yelensky R, Lipson D, Miller VA, Stephens PJ, Subbiah V and Pal SK. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer 2016; 122: 702-711.","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/jclinpath-2021-207855","article-title":"Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort","volume":"76","author":"Kullmann","year":"2023","unstructured":"Kullmann F, Strissel PL, Strick R, Stoehr R, Eckstein M, Bertz S, Wullich B, Sikic D, Wach S, Taubert H, Olbert P, Heers H, Lara MF, Macias ML, Matas-Rico E, Lozano MJ, Prieto D, Hierro I, van Doeveren T, Bieche I, Masliah-Planchon J, Beaurepere R, Boormans JL, Allory Y, Herrera-Imbroda B, Hartmann A and Weyerer V. Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. J Clin Pathol 2023; 76: 126-132.","journal-title":"J Clin Pathol"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Fujii Y, Sato Y, Suzuki H, Kakiuchi N, Yoshizato T, Lenis AT, Maekawa S, Yokoyama A, Takeuchi Y, Inoue Y, Ochi Y, Shiozawa Y, Aoki K, Yoshida K, Kataoka K, Nakagawa MM, Nannya Y, Makishima H, Miyakawa J, Kawai T, Morikawa T, Shiraishi Y, Chiba K, Tanaka H, Nagae G, Sanada M, Sugihara E, Sato TA, Nakagawa T, Fukayama M, Ushiku T, Aburatani H, Miyano S, Coleman JA, Homma Y, Solit DB, Kume H and Ogawa S. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell 2021; 39: 793-809, e8.","DOI":"10.1016\/j.ccell.2021.05.008"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00345-016-1871-x","article-title":"HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","unstructured":"Soria F, Moschini M, Haitel A, Wirth GJ, Karam JA, Wood CG, Roupret M, Margulis V, Karakiewicz PI, Briganti A, Raman JD, Kammerer-Jacquet SF, Mathieu R, Bensalah K, Lotan Y, Ozsoy M, Remzi M, Gust KM and Shariat SF. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World J Urol 2017; 35: 251-259.","journal-title":"World J Urol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.6004\/jnccn.2018.7264","article-title":"Oncogenic addiction to ERBB2 signaling predicts response to trastuzumab in urothelial cancer","volume":"17","author":"Karass","year":"2019","unstructured":"Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JM, Scherr DS, Sboner A, Tagawa ST, Molina AM, Elemento O, Nanus DM and Faltas BM. Oncogenic addiction to ERBB2 signaling predicts response to trastuzumab in urothelial cancer. J Natl Compr Canc Netw 2019; 17: 194-200.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience","volume":"29","author":"Guercio","year":"2023","unstructured":"Guercio BJ, Sarfaty M, Teo MY, Ratna N, Duzgol C, Funt SA, Lee CH, Aggen DH, Regazzi AM, Chen Z, Lattanzi M, Al-Ahmadie HA, Brannon AR, Shah R, Chu C, Lenis AT, Pietzak E, Bochner BH, Berger MF, Solit DB, Rosenberg JE, Bajorin DF and Iyer G. Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clin Cancer Res 2023; 29: 4586-4595.","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.2217\/fon-2021-1629","article-title":"Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial","volume":"18","author":"Pal","year":"2022","unstructured":"Pal SK, Somford DM, Grivas P, Sridhar SS, Gupta S, Bellmunt J, Sonpavde G, Fleming MT, Lerner SP, Loriot Y, Hoffman-Censits J, Valderrama BP, Andresen C, Schnabel MJ, Cole S and Daneshmand S. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol 2022; 18: 2599-2614.","journal-title":"Future Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12885-022-09376-9","article-title":"PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth","volume":"22","author":"Bhattacharjee","year":"2022","unstructured":"Bhattacharjee S, Sullivan MJ, Wynn RR, Demagall A, Hendrix AS, Sindhwani P, Petros FG and Nadiminty N. PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. BMC Cancer 2022; 22: 312.","journal-title":"BMC Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/s12885-021-08085-z","article-title":"Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)","volume":"21","author":"Grivas","year":"2021","unstructured":"Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D and Chowdhury S. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC Cancer 2021; 21: 593.","journal-title":"BMC Cancer"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Papai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019; 380: 1929-1940.","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"22","author":"Rugo","year":"2021","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC and Chia S. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 2021; 22: 489-498.","journal-title":"Lancet Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41421-023-00523-5","article-title":"Structure and dynamics of the EGFR\/HER2 heterodimer","volume":"9","author":"Bai","year":"2023","unstructured":"Bai X, Sun P, Wang X, Long C, Liao S, Dang S, Zhuang S, Du Y, Zhang X, Li N, He K and Zhang Z. Structure and dynamics of the EGFR\/HER2 heterodimer. Cell Discov 2023; 9: 18.","journal-title":"Cell Discov"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2119\/molmed.2013.00108","article-title":"Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer","volume":"19","author":"Grivas","year":"2013","unstructured":"Grivas PD, Day KC, Karatsinides A, Paul A, Shakir N, Owainati I, Liebert M, Kunju LP, Thomas D, Hussain M and Day ML. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer. Mol Med 2013; 19: 367-376.","journal-title":"Mol Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.2353\/ajpath.2010.090872","article-title":"Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma","volume":"176","author":"Hansel","year":"2010","unstructured":"Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, De Marzo A, Steinle RE, Hsi ED, Theodorescu D, Ching CB and Eng C. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 2010; 176: 3062-3072.","journal-title":"Am J Pathol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12885-016-2570-0","article-title":"PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma","volume":"16","author":"Ross","year":"2016","unstructured":"Ross RL, McPherson HR, Kettlewell L, Shnyder SD, Hurst CD, Alder O and Knowles MA. PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma. BMC Cancer 2016; 16: 553.","journal-title":"BMC Cancer"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","article-title":"Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase","volume":"7","author":"Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D, Zehir A, Berger MF, Seshan VE, Chan TA and Morris LGT. Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase. JAMA Oncol 2021; 7: 739-743.","journal-title":"JAMA Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","unstructured":"Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Flechon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC and Ravaud A. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748-757.","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial","volume":"9","author":"Yap","year":"2023","unstructured":"Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R and Konstantinopoulos PA. Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial. JAMA Oncol 2023; 9: 40-50.","journal-title":"JAMA Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"SK","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D’Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R and Snedeker J. Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2023; 21: 1281-1301.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Burki TK. Erdafitinib for advanced urothelial carcinoma. Lancet Oncol 2019; 20: e469.","DOI":"10.1016\/S1470-2045(19)30522-4"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O’Hagan A, Avadhani A and Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019; 381: 338-348.","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Burki TK. Enfortumab vedotin shows promise in solid tumours. Lancet Oncol 2020; 21: e133.","DOI":"10.1016\/S1470-2045(20)30089-9"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M and Petrylak DP. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021; 384: 1125-1135.","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000502116","article-title":"Vinflunine in metastatic urothelial carcinoma of the bladder in progression after a platinum-containing regimen","volume":"97","author":"De Luca","year":"2019","unstructured":"De Luca R, Profita G, Vella M and Cicero G. Vinflunine in metastatic urothelial carcinoma of the bladder in progression after a platinum-containing regimen. Oncology 2019; 97: 341-347.","journal-title":"Oncology"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/10\/ajcr0168674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:48:52Z","timestamp":1768898932000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/10\/ajcr0168674.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/rgvc7978","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}